Brief Report: Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced Non–Small-Cell Lung Cancer With Sensitizing EGFR Mutation
Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.11.028
Full Text
Open PDFAbstract
Available in full text
Date
March 1, 2019
Authors
Publisher
Elsevier BV